Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchRegdanvimabRegdanvimab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Regdanvimab for COVID-19: real-time meta analysis of 11 studies

@CovidAnalysis, July 2024, Version 8V8
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lee 59% 0.41 [0.02-10.1] death 0/234 1/544 Improvement, RR [CI] Treatment Control Lee (PSM) 82% 0.18 [0.06-0.52] severe case 234 (n) 234 (n) Lee (PSM) 45% 0.55 [0.30-1.00] oxygen 234 (n) 234 (n) Lee 8% 0.92 [0.87-0.97] no disch. 234 (n) 544 (n) Lee 77% 0.23 [0.09-0.58] no disch. 5/234 50/544 Streinu-.. (DB RCT) -151% 2.51 [0.10-61.1] ventilation 1/203 0/104 Streinu-.. (DB RCT) 54% 0.46 [0.18-1.15] oxygen 8/203 9/104 Streinu-.. (DB RCT) 49% 0.51 [0.21-1.25] hosp. 9/203 9/104 Streinu-.. (DB RCT) 49% 0.51 [0.21-1.25] progression 9/203 9/104 Streinu-.. (DB RCT) 35% 0.65 [0.49-0.86] recov. time 203 (n) 104 (n) Streinu-.. (DB RCT) 2% 0.98 [0.81-1.20] viral time 203 (n) 104 (n) Chae 71% 0.29 [0.01-5.76] death 0/25 2/99 Chae 64% 0.36 [0.05-2.66] ventilation 1/25 11/99 Chae 9% 0.91 [0.68-1.23] hosp. time 25 (n) 99 (n) Park (PSM) 79% 0.21 [0.12-0.34] progression 19/377 81/377 Park (PSM) 13% 0.87 [0.83-0.91] hosp. time 377 (n) 377 (n) Jang 60% 0.40 [0.26-0.63] oxygen 17/73 79/137 Jang 44% 0.56 [0.33-0.94] no disch. 14/73 47/137 Jang 35% 0.65 [0.50-0.85] no disch. 34/73 98/137 Jang 13% 0.87 [0.79-0.96] hosp. time 73 (n) 137 (n) Kim (DB RCT) 50% 0.50 [0.05-5.53] death 1/656 2/659 Kim (DB RCT) 86% 0.14 [0.01-2.77] ventilation 0/656 3/659 Kim (DB RCT) 91% 0.09 [0.01-1.64] ICU 0/656 5/659 Kim (DB RCT) 69% 0.31 [0.17-0.54] oxygen 15/656 49/659 Kim (DB RCT) 69% 0.31 [0.18-0.54] hosp. 16/656 52/659 Kim (DB RCT) 70% 0.30 [0.18-0.52] progression 16/656 53/659 Kim (DB RCT) 72% 0.28 [0.16-0.51] progression 14/446 48/434 Kim (DB RCT) 32% 0.68 [0.60-0.77] viral+ 612 (n) 618 (n) Jang 70% 0.30 [0.01-7.25] death 0/418 1/304 Jang 12% 0.88 [0.84-0.92] hosp. time 418 (n) 304 (n) Jang 49% 0.51 [0.41-0.64] oxygen 92/418 130/304 Jang 68% 0.32 [0.22-0.48] no disch. 31/418 70/304 Kim 51% 0.49 [0.34-0.71] progression 1,095 (n) 1,119 (n) Kim 34% 0.67 [0.35-1.27] progression 1,095 (n) 1,119 (n) Kim 32% 0.68 [0.56-0.82] oxygen 1,095 (n) 1,119 (n) Kim 4% 0.96 [0.70-1.33] oxygen 1,095 (n) 1,119 (n) Hwang 83% 0.17 [0.02-1.37] death 1/189 6/189 Hwang 92% 0.08 [0.01-0.78] death 0/189 6/189 Hwang 0% 1.00 [0.06-15.9] ventilation 1/189 1/189 Hwang 33% 0.67 [0.28-1.59] ICU 8/189 12/189 Hwang 55% 0.45 [0.25-0.82] oxygen 14/189 31/189 Lee 59% 0.41 [0.22-0.76] death 10/77 49/153 Choi 86% 0.14 [0.01-2.56] death 0/65 5/333 Choi 76% 0.24 [0.07-0.60] oxygen 4/65 67/333 Regdanvimab COVID-19 outcomes c19early.org July 2024 Favors regdanvimab Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit